Clinical Trial Agreements (CTAs) are used for studies conducted in humans to determine the safety and efficacy of agents and devices.
The NCI Center for Cancer Research (CCR) is dedicated to reducing the burden of cancer through exploration, discovery, and the translation of novel approaches into compassionate and effective care for all cancer patients. The NCI TTC has developed two CTAs that can be used for clinical trials conducted at the NIH: CTA Where IC holds the IND and CTA Where Entity holds the IND . IC means an Institute or Center of the National Institutes of Health; Entity typically means a company. Additional information is available for clinical trials conducted at the NCI.
There are unique partnership opportunities with the NCI to facilitate oncology drug discovery and development through the NCI Experimental Therapeutics Program (NExT).